SCHEMBL6554648

SCHEMBL6554648

COc1ccc(C(=O)C(C)C(=O)O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.64
CYP1A2 P05177 1/20 0.64
CA1 P00915 5/20 0.59
CA2 P00918 5/20 0.59
CES2 O00748 2/20 0.55
CES1 P23141 2/20 0.55
PARP1 P09874 1/20 0.52
PARP10 Q53GL7 1/20 0.52
PARP2 Q9UGN5 1/20 0.52
PARP4 Q9UKK3 1/20 0.52
MAPT P10636 2/20 0.50
POLB P06746 1/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
LDHA P00338 1/20 0.50
PLK1 P53350 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A4 P31645 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5217024 0.90 CES2 (0.61) ALDH1A1CYP1A2CA1CA2CES2
SCHEMBL29589535 0.87 CES2 (0.67) ALDH1A1CYP1A2CA1CA2CES2
SCHEMBL9369669 0.86 CA1 (0.59) ALDH1A1CYP1A2CA1CA2CES2
1,4-Dimethoxybenzene SCHEMBL27728351 0.86 LDHA (0.59) ALDH1A1CYP1A2CA1CA2CES2
SCHEMBL391885 0.85 ALDH1A1 (0.56) ALDH1A1CYP1A2CA1CA2CES2
SCHEMBL9614771 0.83 ALDH1A1 (0.62) ALDH1A1CYP1A2CA1CA2CES2
SCHEMBL18082660 0.83 PLK1 (0.56) ALDH1A1CYP1A2CA1CA2CES2
SCHEMBL28883199 0.82 ALDH1A1 (0.66) ALDH1A1CYP1A2CA1CA2CES2
SCHEMBL12453 0.82 CES2 (0.61) ALDH1A1CYP1A2CA1CA2CES2
SCHEMBL6981600 0.81 PARP10 (0.55) ALDH1A1PARP10MAPTPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102627670-B Aryl alkyl acid-cyclophosphamide derivative as well as preparation method and application thereof UNIV SHIJIAZHUANG 2014-11-26 CN claimed
CN-102070438-A Preparation method of gamma-p-methoxyphenyl butyrate TIANJIN YIHENG TECHNOLOGY DEV CO LTD 2011-05-25 CN claimed
CN-102060692-A Preparation method of gamma-(p-methoxyphenyl) butyric acid HUNAN TIANCHENG PHARMACEUTICAL COMPANY LTD 2011-05-18 CN claimed
CN-102627670-B Aryl alkyl acid-cyclophosphamide derivative as well as preparation method and application thereof UNIV SHIJIAZHUANG 2014-11-26 CN disclosed
CN-102627670-A Aryl alkyl acid-cyclophosphamide derivative as well as preparation method and application thereof UNIV SHIJIAZHUANG 2012-08-08 CN disclosed
CN-102070438-A Preparation method of gamma-p-methoxyphenyl butyrate TIANJIN YIHENG TECHNOLOGY DEV CO LTD 2011-05-25 CN disclosed
CN-102060685-A Synthesis method of 2,4,5-trimethoxy-alpha-halogenated acetophenone HUNAN TIANCHENG PHARMACEUTICAL COMPANY LTD 2011-05-18 CN disclosed
CN-102060692-A Preparation method of gamma-(p-methoxyphenyl) butyric acid HUNAN TIANCHENG PHARMACEUTICAL COMPANY LTD 2011-05-18 CN disclosed
EP-1016653-B1 Preparation of high-dye yield couplers and intermediates useful therein EASTMAN KODAK CO (US) 2004-02-25 EP disclosed
US-6602895-B2 Inhibitors of factor Xa with a neutral P1 specificity group BRISTOL-MYERS SQUIBB COMPANY 2003-08-05 US disclosed
US-20030092740-A1 Inhibitors of factor Xa with a neutral P1 specificity group GALEMMO ROBERT A (US) 2003-05-15 US disclosed
US-5877202-A Indole derivatives useful to treat estrogen-related neoplasms and disorders AVENTISUB II INC. 1999-03-02 US disclosed
WO-1998057937-A2 INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1998-12-23 WO disclosed
EP-0746544-B1 NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS MERRELL PHARMA INC (US) 1998-09-09 EP disclosed
EP-0746544-A1 NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS MERRELL PHARMACEUTICALS INC. (US) 1996-12-11 EP disclosed
WO-1995022524-A1 NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS MERRELL PHARMACEUTICALS INC. (US) 1995-08-24 WO disclosed
EP-0412933-B1 Coating compositions CIBA GEIGY AG (CH) 1994-09-14 EP disclosed
US-5183842-A Mixture of ketoacid and amine with film-forming binder, curing CIBA-GEIGY CORPORATION (US) 1993-02-02 US disclosed
US-5128396-A Corrosion inhibiting primers on metallic substrates CIBA-GEIGY CORPORATION (US) 1992-07-07 US disclosed
EP-0412933-A1 Coating compositions CIBA-GEIGY AG (CH) 1991-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092740-A1 Inhibitors of factor Xa with a neutral P1 specificity group F12, F11, SERPINC1 ALDH1A1 1329/4885CYP1A2 995/4885CA1 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.